Regeneron Pharmaceuticals, Inc. (VIE:REGN)
Austria · Delayed Price · Currency is EUR | Market Cap | 67.75B +37.2% |
| Revenue (ttm) | 13.60B +9.3% |
| Net Income | 3.79B -2.9% |
| EPS | 35.39 +1.9% |
| Shares Out | n/a |
| PE Ratio | 17.88 |
| Forward PE | 11.75 |
| Dividend | 3.12 (0.46%) |
| Ex-Dividend Date | May 20, 2026 |
| Volume | n/a |
| Open | 669.40 |
| Previous Close | 662.60 |
| Day's Range | 668.50 - 673.60 |
| 52-Week Range | 470.80 - 699.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron announces Health Canada approval of new indication for Libtayo
Regeneron (REGN) Canada announced that Health Canada has issued a Notice of Compliance for Libtayo for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma at high risk…
Regeneron price target raised to $1,030 from $1,000 at Guggenheim
Guggenheim raised the firm’s price target on Regeneron (REGN) to $1,030 from $1,000 and keeps a Buy rating on the shares following what the firm calls ” a clean beat…
Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg
BENGALURU, India & BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #biosimilar--Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron's Eylea® 2 mg, Used to Treat Various Types of Ophth...
Regeneron price target raised to $740 from $700 at Citi
Citi raised the firm’s price target on Regeneron (REGN) to $740 from $700 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology space post…
Regeneron price target raised to $737 from $696 at RBC Capital
RBC Capital raised the firm’s price target on Regeneron (REGN) to $737 from $696 and keeps a Sector Perform rating on the shares. The company reported strong sales across the…
Regeneron price target raised to $758 from $730 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $758 from $730 and keeps an Equal Weight rating on the shares after “a solid 2Q beat on both…
Regeneron price target raised to $891 from $856 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Regeneron (REGN) to $891 from $856 and keeps a Buy rating on the shares. Dupixent’s beat in Q2 raises the…
Regeneron price target raised to $795 from $750 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Regeneron (REGN) to $795 from $750 and keeps an Overweight rating on the shares. Regeneron’s Q2 results reduced near-term…
Regeneron price target raised to $761 from $742 at Baird
Baird raised the firm’s price target on Regeneron (REGN) to $761 from $742 and keeps a Neutral rating on the shares. The firm updated its model following impressive Q2 results…
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 ...
Regeneron price target raised to $750 from $700 at Wells Fargo
Wells Fargo raised the firm’s price target on Regeneron (REGN) to $750 from $700 and keeps an Equal Weight rating on the shares. The firm believes the company’s Q2 reinforces…
Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026
Revenue grew 17% year-over-year to $4.3B, with double-digit EPS growth and record sales for Dupixent, EYLEA HD, and Libtayo. Pipeline advances and upcoming regulatory milestones support a strong outlook, while robust cash flow enables continued R&D and shareholder returns.
Regeneron Pharmaceuticals Earnings release: Q2 2026
Regeneron Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Regeneron Pharmaceuticals Quarterly report: Q2 2026
Regeneron Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Regeneron Pharmaceuticals Slides: Q2 2026
Regeneron Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
08:17 EDT Regeneron (REGN) cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
Regeneron beats quarterly estimates on eczema drug strength, shares rise
Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea.
Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20
Reports Q2 revenue $4.3B, consensus $3.83B. “Regeneron (REGN) delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength...
Regeneron Reports Second Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update.
REGN Stockholders Have Rights – If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceut...
The Scientist With 1,000 Patents Fueling a Drug Powerhouse
At Regeneron, George Yancopoulos is the rare scientist and executive who drives growth with discoveries instead of acquisitions.
$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FD...
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $REGN #BFA--Regeneron Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA.
Regeneron price target raised to $1,000 from $995 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $1,000 from $995 and keeps a Buy rating on the shares. The firm is revising some of…